CD8A and neoplasm: In this setting, the improved efficacy of the vaccine is characterized by increased quantity and quality, limited exhaustion of CD8+ T-cell responses and a TME remodeled to acquire inflammatory properties allowing for the maintenance of anti-tumor CTL capacities.